Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite^®) solution in the treatment of ocular infections

References

• AmsdenGWAdvanced-generation macrolides: tissue directed antibioticsInt J Antimicrob Agents200118Suppl 1S11S1511574189
   PubMed Web of Science ®Google Scholar
• AkpekEKVittitowJVerhoevenRSOcular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulationJ Ocul Pharmacol Ther200925543343919857105
   PubMed Web of Science ®Google Scholar
• AbelsonMBHellerWShapiroAMClinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trialAm J Ophthalmol2008145695996518374301
   PubMed Web of Science ®Google Scholar
• RetsemaJGirardASchelklyWSpectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring-macrolide with improved potency against gram-negative organismsAntimicrob Agents Chemother19873112193919472449865
   PubMed Web of Science ®Google Scholar
• WestSKAzithromycin for control of trachomaCommunity Eye Health19991232555617492006
   PubMedGoogle Scholar
• IanaroAIalentiAMaffiaPAnti-inflammatory activity of macrolide antibioticsJ Pharmacol Exp Ther2000292115616310604943
   PubMed Web of Science ®Google Scholar
• PiacentiniGLPeroniDGBodiniAAzithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary reportAllergy Asthma Proc200728219419817479604
   PubMed Web of Science ®Google Scholar
• HoweRASpencerRCMacrolides for the treatment of Pseudomonas aeruginosa infections?J Antimicrob Chemother19974021531559301978
   PubMed Web of Science ®Google Scholar
• HoffmannNLeeBHentzerMAzithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(−/−) miceAntimicrob Agents Chemother200751103677368717620382
   PubMed Web of Science ®Google Scholar
• AmsdenGWAnti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?J Antimicrob Chemother2005551102115590715
   PubMed Web of Science ®Google Scholar
• JacotJLJacotTASheppardJDEvaluation of MMP 2/9 modulation by AzaSite and DuraSite in human corneal epithelial cells and bovine corneal endothelial cells in vitroPoster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting2008 Apr 28Fort Lauderdale, FL49 abstract 1985.
   Google Scholar
• SadraiZHajrasoulihaARChauhanSSabanDRDastjerdiMHDanaREffect of topical azithromycin on corneal innate immune responseInvest Ophthalmol Vis Sci20115252525253121296809
   PubMed Web of Science ®Google Scholar
• BowmanLSiEPangJArchibadRFriedlaenderMDevelopment of a topical polymeric mucoadhesive ocular delivery system for azithromycinJ Ocul Pharmacol Ther200925213313919284320
   PubMed Web of Science ®Google Scholar
• BowmanLMSiEPangJFriedlaenderMDevelopment of a commercial eye drop formulation of azithromycinPoster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting2007 May 6–10Fort Lauderdale, FL48 e-Abstract 772.
   Google Scholar
• AbelsonMProtzkoEShapiroAGarces-SoldanaABowmanL1% azithromycin in DuraSite Clinical Study GroupA randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitisClin Ophthalmol20071217718219668507
   PubMedGoogle Scholar
• WuECKowalskiRPRomanowskiEGMahFSGordonYJShanksRMAzaSite® inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitroJ Ocul Pharmacol Ther20101226655756221029017
   PubMed Web of Science ®Google Scholar
• HarperDGChenCEFriedlaenderMHControlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitisCLAO J19952142562608565196
   PubMedGoogle Scholar
• LiuPAllaudeenHChandraRComparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimenAntimicrob Agents Chemother200751110310917060516
   PubMed Web of Science ®Google Scholar
• SchentangJJBallowCHTissue-directed pharmacokineticsAm J Med1991913A5S11S
   Web of Science ®Google Scholar
• GladueRPSniderMEIntracellular accumulation of azithromycin by cultured human fibroblastsAntimicrob Agents Chemother1999346105610602168141
   PubMed Web of Science ®Google Scholar
• GladueRPBrightGMIsaacsonRENewborgMFIn vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infectionAntimicrob Agents Chemother19893332772822543276
   PubMed Web of Science ®Google Scholar
• RappRPPharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactionsAnn Pharmacother1998327–87857939681095
   PubMed Web of Science ®Google Scholar
• KarciogluZAAhmedWSRainesDEl-YazigiAPharmacokinetics of azithromycin rabbit lacrimal glands and conjunctivaOphthalmic Res199931147529831822
   PubMed Web of Science ®Google Scholar
• O’DayDMHeadFSFouldsGRobinsonRDWilliamsTEFerrainaRAOcular pharmacokinetics of orally administered azithromycin in rabbitsJ Ocul Pharmacol19941046336417714407
   PubMedGoogle Scholar
• TabbaraKFAl-KharashiSAAl-MansouriSMOcular levels of azithromycinArch Ophthalmol199811612162516289869792
   PubMedGoogle Scholar
• AmarTCaillaudTElenaPOcular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbitsCurr Eye Res200833214915818293185
   PubMed Web of Science ®Google Scholar
• Investigator’s Brochure, Azithromycin Ophthalmic Solution 1%, ed 2.0Inspire Pharmaceuticals, IncRaleigh, NC11122009
   Google Scholar
• StewartWCCreanCSZinkRCBrubakerKHaqueRHwangDGPharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimensAm J Ophthalmol201015074475120813346
   PubMed Web of Science ®Google Scholar
• TorkildsenGO’BrienTPConjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteersClin Ther200830112005201419108788
   PubMed Web of Science ®Google Scholar
• SiPCCheungPSBowmanLHosseiniKOcular pharmacokinetics of Azasite Xtra – 2% azithromycin formulated in a DuraSite delivery systemCurr Eye Res200934648549119899983
   PubMed Web of Science ®Google Scholar
• AmacherDEEllisJHJoyceAJPreclinical toxicology studies with azithromycin: genetic toxicology evaluationMutat Res199330079907685497
   PubMed Web of Science ®Google Scholar
• StadnickiSWKessedijanMStadlerJTachibanaMPreclinical reproductive and teratology studies with azithromycinOyo Yakuri/Pharmacometrics1996518595
   Google Scholar
• GranetDLichtensteinSJOnofneyBKatzJAAn assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSiteClin Ophthalmol20071451952519668531
   PubMedGoogle Scholar
• OhtaniHTaninakaCHanadaEComparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in ratsAntimicrob Agents Chemother200044102630263710991836
   PubMed Web of Science ®Google Scholar
• NessPJMamalisNWernerLAn anterior chamber toxicity study evaluating Besivance, AzaSite, and CiprofloxacinAm J Ophthalmol2010150449850420678751
   PubMed Web of Science ®Google Scholar
• SealDVBarrettSPMcGillJIAetiology and treatment of acute bacterial infection of the external eyeBr J Ophthalmol1982663573607082605
   PubMed Web of Science ®Google Scholar
• AzaSite [package insert]Durham, NCinspire Pharmaceuticals2008
   Google Scholar
• AbelsonMHellerWEfficacy of azithromycin 1% eye drops vs vehicle as first line therapy for bacterial conjunctivitis Unpublished study the Cochrane Register of Controlled Trials (CENTRAL).2006 ID CN00634804.
   Google Scholar
• HellerWAbelsonMGroup TASSafety and tolerabiltiy of azithromycin 1% eye drops as anti-infective therapy for bacterial conjunctivitis Unpublished study for the Cochrane Register of Controlled Trials (CENTRAL). Study ID CN 00634521.
   Google Scholar
• ProtzkoEBowmanLAbelsonMShapieroAGroup TACSPhase 3 safety comparisons for 1% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitisInvest Ophthalmol Vis Sci20074883425342917652708
   PubMed Web of Science ®Google Scholar
• CochereauIMeddeb-OuertaniAKhairallahM3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and childrenBr J Ophthalmol200791446546917050578
   PubMed Web of Science ®Google Scholar
• Bremond-GignacDMariani-KurkdjianPBeresniakAEfficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patientsPediatr Infect Dis J201029322222619935122
   PubMed Web of Science ®Google Scholar
• RobertPYBourcierTMeddeb-OuertaniA[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]J Fr Ophtalmol2010334241248 French.20223555
   PubMed Web of Science ®Google Scholar
• SealDVMcGillJIJacobsPLiakosGMGouldingNJMicrobial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitisBr J Ophthalmol19856986046114016059
   PubMed Web of Science ®Google Scholar
• SmithREFlowersCWChronic blepharitis: a reviewCLAO J19952132002077586480
   PubMedGoogle Scholar
• McDermottAMPerezVHuangAJPathways of corneal and ocular surface inflammation: a perspective from the cullen symposiumOcul Surf20053Suppl 4S131S13817216102
   PubMed Web of Science ®Google Scholar
• LuchsJAzithromycin in DuraSite for the treatment of blepharitisClin Ophthalmol2010468168820689782
   PubMedGoogle Scholar
• FoulksGNBorchmanDYappertMKimSHMcKayJWTopical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterationsCornea201029778178820489573
   PubMed Web of Science ®Google Scholar
• LuchsJEfficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitisAdv Ther200825985887018781287
   PubMed Web of Science ®Google Scholar
• TrattlerWBKuhnKLHaqueRZinkRCSallKNLuchsJTopical azithromycin improves blepharitis signs and symptomsPresented at The American Society of Cataract and Refractive Surgery2009 Apr 3–8San Francisco, CA
   Google Scholar
• HaqueRMTorkildsenGLBrubakerKMulti-center, open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitisCornea201029887187720508503
   PubMed Web of Science ®Google Scholar
• OpitzDLTylerKFEfficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitisClin Exp Optom201194220020621083761
   PubMed Web of Science ®Google Scholar
• TorkildsenGLCockrumPMeierEHammondsWMSilversteinBSilversteinSEvaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitisCurr Med Res Opin201127117117821138337
   PubMed Web of Science ®Google Scholar
• MariottiSPPrüssAWorld Health OrganizationThe safe strategy. Preventing trachoma. A guide for environmental sanitation and improved hygiene WHO/PBD/GET/00.7/ Rev 1.2001136
   Google Scholar
• ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ20048284485115640920
   PubMed Web of Science ®Google Scholar
• TabbaraKFAbu-El-AsrarAAl-OmarOChoudhuryAHAl-FaisalZSingle dose azithromycin in the treatment of trachoma. A randomized controlled studyOphthalmology199610358428468637698
   PubMed Web of Science ®Google Scholar
• CochereauIGoldschmidtPGoepoguiAEfficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, doublemasked clinical trialBr J Ophthalmol200791566767217005549
   PubMed Web of Science ®Google Scholar
• AmzaAGoldschmidtPEinterzEElimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye dropsPLoS Negl Trop Dis2010411e89521124889
   PubMed Web of Science ®Google Scholar
• HuguetPBellaLEinterzEMGoldschmidtPBensaidPMass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectivenessBr J Ophthalmol201094215716019692356
   PubMed Web of Science ®Google Scholar